Legend Biotech, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology, raised $150m in series A funding round. The investors include Hudson Bay Capital Management, Johnson & Johnson Innovation - JJDC, Lilly Asia Ventures, Vivo Capital, Smallcap World Funds, and RA Capital Management. Proceeds from the financing will be used to advance the research and development and commercialization of Legend’s pipeline programs and expansion of manufacturing facilities, enhancement of its research and development platform, as well as general corporate expenses.